2 / 22
Volume 7
OMICS Journal of Radiology
Radiology and Oncology 2018
July 16-17, 2018
Page 28
conference
series
.com
July 16-17, 2018 Dubai, UAE
Radiology and Oncology
2
nd
World Congress on
Current concepts of theranostic approach in precision oncology : The changing paradigms
T
he term theranostics is the combination of a diagnostic tool that helps to define the right therapeutic tool for specific
disease. It signifies the “we treat what we see & see what we treat” concept. A diagnostic radionuclide labelled with the
target and once expression is documented, the same target is labelled with a therapeutic radionuclide and treatment is executed.
In addition a molecular biomarker based targeted treatment can be tailored with either biomarker or molecular imaging. The
concept is utilized in few malignancies especially NET & prostate cancer currently. Molecular imaging modalities exploit
the receptor expression aspects of the pathophysiology for both diagnostic imaging & therapeutic purposes. The receptor
expression changes with tumor grades and hormone resistance. We have reported excellent sensitivity and detection capability
of both primary and metastatic disease. Besides evaluation of recurrence, 68Ga-labelled radiopharmaceuticals can be utilized
for detection of metastasis and selection of patients for therapy. 68Ga- DOTA or PSMA serves the basis of treatment of these
conditions with 177Lu . Based on the theranostic concept the aims of treatment with 177Lu are to improve outcome by early
interventions in suboptimal responders, sparing low risk patients from over treatment, reduce treatment related side effects,
ensure effective palliation & improve quality of life. Tumor targeting with 177Lu DOTA or PSMA saves normal tissue &
delivers high dose to tumor. Easy radiopharmaceutical labelling & high expression in all cancer cells makes it an optimal target
for radionuclide therapy, with a low toxicity profile. In our experience at RGCI & RC (our institute) we have seen objective
regression in lesions and symptomatic relief. It has been found to be a safe & effective method for treating end stage androgen
independent, progressive CRPC and metastatic NET. Similarly a personalized treatment model based on molecular biomarkers
and imaging in breast cancer is possible based on imaging of estrogen receptors and 18F FES imaging in breast cancer. In this
presentation, I am going to discuss our experience in precision oncology based on the above concepts.
Biography
Partha S Choudhury is an internationally acclaimed leading Nuclear Medicine Physician of India with special interest in Radionuclide Therapy of various types
of cancers. He has more than 25 years of experience in Nuclear Oncology. He is heading the department of Nuclear Medicine in Rajiv Gandhi Cancer Institute
& Research Centre Delhi India since 1998 and has been instrumental in its sustained growth over the last 20 years. He has introduced and standardized new
procedures in the department both in terms of disease specific diagnostic, molecular imaging & molecular therapy. He is an invited speaker in conferences
and symposiums across many countries, the main ones being United Kingdom, Austria, South Africa and South America. He is an avid clinical researcher with
publications in peer reviewed journals. He is a technical co-operation consultant & participant of co-ordinated research projects of International Atomic Energy
Agency (IAEA) Vienna
pschoudhary@hotmail.comPartha S Choudhury
Rajiv Gandhi Cancer Institute & Research Centre, India
Partha S Choudhury, OMICS J Radiol 2018, Volume 7
DOI: 10.4172/2167-7964-C1-021